CyberMed is a powerful form of AI edge computing and is intended to streamline efficiencies and assist medical professionals in their practice. Credit: SOMKID THONGDEE / Shutterstock.

Inspira Technologies has received its first order for the INSPIRA ART100 systems from Glo-Med Networks, marking a significant milestone in its expansion plan within the US market.

The initial order includes five units expected to be shipped in the fourth quarter of this year, with the potential for an additional 20 systems subject to further agreement.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The INSPIRA ART100 systems are part of the company’s strategy to penetrate the $19bn mechanical ventilator market with its next-generation technology.

The systems are designed to potentially replace mechanical ventilation, offering an advanced solution.

These units are intended for use in US hospitals.

Inspira plans to provide hospitals with an option for the integrated HYLA Blood Sensor and INSPIRA ART (Gen 2) devices, pending the completion of product development and regulatory approvals.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Inspira director, president and co-founder Joe Hayon said: “We continue to develop the breakthrough technologies of tomorrow.

“The INSPIRA ART100 is our first and important step in building the INSPIRA market presence and position in preparation for the INSPIRA ART (Gen 2), which we believe has the potential to provide a new clinical solution with a potentially different intent of use for the mega life support and mechanical ventilation market.”

In March 2024, Inspira said it was seeking approval for its INSPIRA ART100 device to enter the South East Asia and South American markets.

The application for the device, which is intended for patients undergoing cardiopulmonary bypass procedures, was submitted to AMAR, the Israeli Ministry of Health’s medical device regulation unit.